Where does Gmax Biopharm LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Gmax Biopharm LLC ranks #35,528 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Gmax Biopharm LLC hold?

Gmax Biopharm LLC holds 7 US utility patents granted between 2018 and 2023, spanning 4 technology areas.

What is Gmax Biopharm LLC's Innovation Score?

Gmax Biopharm LLC has an Innovation Score of 29.5 out of 100 (31st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Gmax Biopharm LLC focus on?

Gmax Biopharm LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 7 patents, ranking #2,588 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is Gmax Biopharm LLC's patent grant rate increasing or decreasing?

Gmax Biopharm LLC's recent grant velocity is +33% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Gmax Biopharm LLC's patents?

Gmax Biopharm LLC's patents average 14.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Gmax Biopharm LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Gmax Biopharm LLC

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2018–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Gmax ranks #35,528 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#35,528
of 49,997 US assignees by volume: 31st percentile
by Innovation Score (29.5/100): 14.3
avg claims per patent: +33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R35528 · Foreign Corporation #35,528 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 7 grants
MID-PACK #35,528/49,997
PHOTO-FINISH Globe Holding
CPC-NARROW A61P · 4 areas
INNOV-THIN 29.5/100
CLAIMS-RICH 14.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Globe Holding Company LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Gmax’s 29.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (24%) Velocity 6.7 pts (23%) Breadth 7.1 pts (24%) Claim depth 8.6 pts (29%)

Qualcomm Incorporated · highest

85
Gmax Biopharm · this assignee

29
3D Lighting… · lowest

7

What this shows Gmax's Innovation Score is 29.5/100 (31st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Gmax?

Each dot is one of Gmax’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Gmax’s own 14.3 claims/patent is at or below the 14.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Gmax vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Gmax's grants concentrate

Gmax Biopharm LLC is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2018. By volume, Gmax sits between Globe Holding Company LLC and Goer Optical Technology Co., Ltd..

Gmax's three-year grant acceleration

Gmax Biopharm LLC shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Globe Holding

7
Glucovista

7
Glue AB

7
Glux Visual Effec…

7
Go Natural CNG

7
Gogo Heel

7
Golabs

7
Goer Optical Tech…

7
Gmax Biopharm ◀

7

What this shows Gmax holds 7 patents at rank #35,554, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Gmax

By rank, the assignees closest to #35,554 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Gmax's primary technology class.

Gmax's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 31st percentile higher than 31% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Gmax Biopharm LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	14.3%
2019	2	28.6%
2020	1	14.3%
2023	3	42.9%

Which technologies does Gmax Biopharm LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 7

C07K - Peptides 7

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 7

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Gmax Biopharm LLC's patent record in context - here's where to go next.

Gmax Biopharm LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #35,528 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Gmax Biopharm LLC against Globe Holding Company LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.